IPO Year: 2024
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/12/2024 | $40.00 | Neutral | Piper Sandler |
7/9/2024 | $41.00 | Buy | BofA Securities |
7/9/2024 | $45.00 | Buy | Stifel |
7/9/2024 | $42.00 | Overweight | JP Morgan |
7/9/2024 | $44.00 | Overweight | Morgan Stanley |
7/9/2024 | $48.00 | Buy | Longbow |
7/9/2024 | $50.00 | Buy | TD Cowen |
7/9/2024 | Outperform | William Blair | |
7/9/2024 | $47.00 | Buy | Needham |
4 - Tempus AI, Inc. (0001717115) (Reporting)
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in
The strategic collaboration will leverage Tempus' large multimodal datasets to enhance BioNTech's next-generation oncology pipeline Tempus AI, Inc. (NASDAQ:TEM, "Tempus"))), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX, "BioNTech"))), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech's next-generation oncology pipeline. Under this collaboration, Tempus is providing analytical support and computational biology expertis
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY. Tempus Founder and CEO, Eric Lefkofsky, will speak in a fireside discussion at the conference on Wednesday, September 4, 2024 at 8:30 a.m. ET. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides A
BERGEN, Norway, Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to progress as planned. Enrollment in the Ph1b part completed. Data Safety Monitoring Board review of data from the final Ph1b dose cohort supports safety and tolerability of the combination of bemcentinib with standard of care chemo/immunotherapy allowing initiation of the 2nd dose in the Ph2a part. All Ph
Tempus invests $36 million by exercising warrants and purchasing additional shares Personalis, Inc. (NASDAQ:PSNL) and Tempus AI, Inc. (NASDAQ:TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the recent ASCO meeting. Tempus is serving as exclusive commercial partner for Personalis' ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. Following positive reaction and exceptionally strong demand, the companies have agreed to
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay has been published in npj Precision Oncology. Titled, "Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities," the study included analytical validation of an investigational test that detects HLA-LOH based on analysis of data generated from Tempus' FDA-approved, next generation sequencing-based xT CDx assay. The test uses a machine learning model to analyze sequen
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing revenue growth accelerated to 40% year-over-year Expanded into the minimal residual disease (MRD) market with the launch of both tumor-naïve and tumor-informed assays Established a joint venture with Softbank to enter the Japanese market Raised $410.7 million of gross proceeds in initial public offering Net Loss of ($552.2 million), larg
New RNA-based algorithm is now available with the xR assay Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program is part of the larger Tempus Next platform, which is designed to identify care gaps and equip clinicians with actionable insights at the point of care. The new Next program is now available and initially focused on the identification of care gaps associated with the human epide
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified data cohorts and has since expanded into a broader, strategic alliance. Remix is leveraging Tempus' multimodal data to interrogate specific cohorts, including Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) with Tempus' data analytics platform, Lens. The newly expanded scope of work also i
PurISTSM is an RNA expression-based test licensed to Tempus AI to help inform and personalize treatment for patients with pancreatic cancer The PurIST proprietary laboratory analysis (PLA) code is the first common procedural terminology (CPT) code created for algorithm-based analysis of previously sequenced RNA data from a laboratory developed test (LDT) GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that the American Medical Association (AMA) has granted a PLA code for the PurISTSM pancreatic cancer test. PurIST is commercially available under a collaboration agreement with Tempus AI, Inc. (NASDAQ:TEM) and run o
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in
These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Virtu Financial, Inc. (NASDAQ:VIRT) shares jumped 30.04% after reporting better-than-expected Q2 financial results. V.F. Corporation (NYSE:VFC) stock upped 22.38% after the company announced it entered into a Stock and Asset Purchase Agreement to sell its Supreme brand to EssilorLuxottica (OTC: ESLOF) for $1.5 billion in cash. Several analysts raised their price forecasts on VFC. New Fortress Energy Inc. (NASDAQ:NFE) shares grew 20.19% after the company announced that it achieved First LNG for its initial Fast LNG asset located offshore Altamira, Mexico. Riot Platforms Inc (NASDAQ:
U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s
Available Today for Life Science Research Use OnlyTempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to bring additional immunotherapy-focused algorithmic tests to this growing portfolio, leveraging clinical, laboratory, genomic, and transcriptomic data to identify patients that
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding. What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday. Noubar Afeya
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged work, comprised of:143 peer-reviewed articles, of which 106 were Tempus-authored;291 poster presentations based on clinical and research data presented at major scientific conferences; and31 oral presentations at scientific meeting
William Blair initiated coverage on Tempus AI, Inc (NASDAQ:TEM), citing the company’s ‘differentiated approach and business model.’ Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases from academic medical centers and community-based hospitals. Related: Tempus Could Gain Share In AI Health Care Market Poised To Grow By Over 30%. In June, the company launched an IPO priced at $37 per share via selling 11.1 million shares, with gross proceeds of around $410.7 million. William Blair says the Outperform rating is based on “What we belie
B of A Securities analyst Michael Ryskin initiates coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and announces Price Target of $41.
Tempus AI Inc (NASDAQ:TEM) announced last week it was granted advanced diagnostic laboratory test status for its next-generation sequencing assay. These analysts provide their initial takeaways from the stock. BofA Securities On Tempus Analyst Michael Ryskin initiated coverage with a Buy rating and price target of $41. Providing AI-enabled precision medicine, Tempus brings "the power of advanced technology to healthcare and diagnostics" and delivers personalized therapy decisions, Ryskin said in his initiation note. "This platform is being monetized as a diagnostic offering and by leveraging the power of the database to Biopharma partners," he added. Tempus serves a large tota
William Blair analyst Andrew Brackmann initiates coverage on Tempus AI (NASDAQ:TEM) with a Outperform rating.
JP Morgan analyst Rachel Vatnsdal initiates coverage on Tempus AI (NASDAQ:TEM) with a Overweight rating and announces Price Target of $42.
4 - Tempus AI, Inc. (0001717115) (Reporting)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
3 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
3 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
10-Q - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
S-8 - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
424B4 - Tempus AI, Inc. (0001717115) (Filer)
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00
Stifel initiated coverage of Tempus AI with a rating of Buy and set a new price target of $45.00
JP Morgan initiated coverage of Tempus AI with a rating of Overweight and set a new price target of $42.00
Morgan Stanley initiated coverage of Tempus AI with a rating of Overweight and set a new price target of $44.00
Longbow initiated coverage of Tempus AI with a rating of Buy and set a new price target of $48.00
William Blair initiated coverage of Tempus AI with a rating of Outperform
TD Cowen initiated coverage of Tempus AI with a rating of Buy and set a new price target of $50.00
Needham initiated coverage of Tempus AI with a rating of Buy and set a new price target of $47.00
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D - Tempus AI, Inc. (0001717115) (Filed by)